control
canin
distemp
realist
achiev
use
vaccin
type
vaccin
current
use
describ
togeth
problem
encount
interfer
matern
antibodi
usag
speci
dog
modifi
live
viral
vaccin
use
thirti
year
prove
effect
nevertheless
scope
improv
vaccin
efficaci
recent
develop
genet
recombin
method
describ
practic
effect
measur
control
canin
distemp
present
immun
vaccin
even
classic
hygien
measur
appli
parallel
r
mcclelland
jh
gillespi
wrote
great
deal
could
written
immun
canin
distemp
much
said
past
present
knowledg
test
procedur
less
need
word
approach
success
protect
rel
straightforward
simpl
mcclelland
gillespi
activ
immun
canin
distemp
dog
achiev
use
variou
type
vaccin
activ
immun
practis
sinc
puntoni
describ
use
formaldehydeinactiv
canin
distemp
viru
cdv
infect
dog
brain
tissu
earli
vaccin
prove
incap
control
diseas
activ
immun
becam
success
live
attenu
vaccin
becam
avail
ferretpassag
modifi
vaccin
modifi
hen
egg
viru
vaccin
haig
modifi
cell
cultur
viru
vaccin
rockborn
heterotyp
measl
vaccin
combin
vaccin
purifi
vaccin
norrbi
et
al
iscom
vaccin
de
vri
et
al
prepar
past
year
remain
experiment
stage
present
modifi
live
viru
mlv
vaccin
use
larg
scale
approxim
x
dose
vaccin
use
usa
popul
x
dog
franc
x
dose
use
popul
x
dog
vaccin
distemp
suppli
freezedri
form
combin
compon
adenoviru
parvoviru
parainfluenza
type
viru
sometim
rabi
viru
coronaviru
leptospira
modifi
live
cdv
vaccin
avail
today
either
avian
egg
origin
onderstepoort
strain
canin
cell
cultur
adapt
rockbom
strain
strain
enabl
prepar
effect
vaccin
regulatori
viewpoint
interest
compar
requir
european
author
america
european
pharmacopoeia
european
council
monograph
vaccinum
morbi
carrei
vivum
cryodessicatum
pro
cane
freezedri
canin
distemp
live
vaccin
mention
essenti
criteria
safeti
master
seed
viru
safeti
everi
batch
potenc
specif
requir
emphas
recent
regul
govern
registr
product
european
union
anon
unit
state
america
code
feder
regul
present
two
monograph
relat
canin
distemp
vaccin
one
concern
ferret
avirul
strain
cfr
one
concern
ferret
virul
strain
cfr
monograph
complet
precis
european
monograph
intrins
properti
vaccin
contain
distemp
compon
critic
vaccin
perform
although
industri
scale
cultur
viru
cell
system
rais
special
problem
storag
heatstabl
freezedri
viru
remain
delic
produc
therefor
find
formula
stabil
obtain
best
shelflif
product
combin
vaccin
distemp
compon
alway
least
heatstabl
comparison
adenoviru
parvoviru
compon
method
adapt
result
effect
vaccin
cdv
onderstepoort
cdvo
cdv
rockbom
cdvr
induc
immun
suscept
dog
last
least
one
year
rout
vaccin
compar
suscept
dog
immun
singl
dose
mlvcdvo
vaccin
ccidsodos
observ
better
seroneutr
antibodi
respons
day
postvaccin
intraven
intramuscular
rout
subcutan
rout
log
iv
rout
log
im
rout
log
sc
rout
vaccin
onset
protect
assess
subcutan
intraven
vaccin
group
dog
subsequ
challeng
intracerebr
inocul
virul
snyder
hill
viru
day
singl
inject
vaccin
complet
protect
obtain
within
hour
follow
intraven
vaccin
within
day
follow
subcutan
vaccin
chappui
terr
chappui
et
al
intraven
rout
usual
recommend
vaccin
could
necessari
use
case
emerg
contamin
puppi
time
primari
vaccin
prefer
rout
administr
use
routin
intramuscular
also
mention
immun
possibl
oral
oculonas
rout
chappui
terr
comparison
antibodi
respons
intramuscular
subcutan
rout
cdvo
cdvn
vaccin
strain
equival
titr
confirm
superior
intramuscular
rout
subcutan
cdvr
strain
induc
higher
antibodi
respons
tabl
howev
despit
less
intens
respons
cdvo
strain
dog
seroposit
total
protect
virul
challeng
one
year
singl
vaccin
case
multipl
combin
vaccin
despit
satisfactori
compat
test
often
observ
cdv
antibodi
kinet
alway
poorer
given
rout
administr
ident
vaccin
titr
group
dog
receiv
combin
vaccin
group
receiv
distemp
compon
case
adenoviru
parvoviru
compon
nevertheless
complet
protect
distemp
challeng
still
observ
group
dog
besid
intrins
qualiti
vaccin
presenc
residu
maternallyderiv
antibodi
problem
time
primari
vaccin
new
problem
shown
histor
work
gillespi
establisheda
nomographpredict
earliest
age
vaccin
puppi
base
antibodi
titr
bitch
calcul
half
life
maternallyderiv
antibodi
titr
decay
rate
passiv
antibodi
proport
growth
rate
dog
fig
dog
belong
rapidgrowth
breed
elimin
maternallyderiv
antibodi
quickli
therefor
becom
rapidli
suscept
diseas
recept
immun
thu
maternallyderiv
antibodi
whilst
benefici
earli
protect
infect
disturb
vaccin
immun
could
postul
shown
case
canin
parvoviru
burtonboy
et
al
vaccin
high
titr
like
effect
presenc
residu
maternallyderiv
antibodi
recent
evid
cdv
vaccin
support
chalmer
baxendal
persist
matern
antibodi
wellknown
caus
vaccin
failur
recommend
primari
vaccin
consist
two
consecut
inject
second
given
puppi
around
week
age
complet
disappear
passiv
immun
expect
vaccin
complet
effect
chappui
et
al
terr
et
al
activ
booster
effect
possibl
increas
level
preexist
activ
antibodi
revaccin
experi
booster
effect
observ
dog
exist
seroneutr
antibodi
tine
booster
effect
invers
relat
level
previou
seroneutr
antibodi
titr
kennel
booster
vaccin
establish
homogen
immun
statu
among
bitch
thu
simplifi
vaccin
programm
litter
michel
et
al
heterotyp
measl
viru
vaccin
one
approach
overcom
neutral
maternallyderiv
antibodi
measl
viru
mv
neutral
cdv
antibodi
mv
induc
clinic
protect
cdv
baker
use
mv
vaccin
origin
recommend
puppi
age
week
although
success
field
condit
afterward
combin
attenu
mv
cdv
appli
puppi
age
week
accept
first
gener
howev
puppi
vaccin
boost
vaccin
produc
antibodi
mv
cdv
subsequ
bitch
transfer
antibodi
specif
litter
although
cdv
vaccin
safe
efficaci
advers
reaction
occur
tizard
brook
advers
reaction
often
complex
interact
anim
vaccin
contain
antigen
environ
includ
veterinarian
investig
advers
reaction
three
compon
need
examin
modifi
live
cdv
vaccin
multipli
dog
caus
transient
immunosuppress
thrombocytopenia
straw
revers
virul
rockbom
strain
demonstr
appel
serial
passag
dog
enceph
dog
batch
cdv
vaccin
observ
comwel
et
al
interact
cdv
adenoviru
mlv
vaccin
induc
suppress
lymphocyt
respons
phillip
et
al
canin
parvoviru
infect
potenti
canin
distemp
enceph
attribut
modifi
live
viru
vaccin
krakowka
et
al
parallel
drawn
latter
observ
epidemiolog
observ
last
fifteen
year
fact
emerg
canin
parvoviru
distemp
larg
disappear
veterinari
practic
wherea
sinc
except
observ
distemp
sometim
form
epidem
even
urban
dog
popul
blixenkronemol
et
al
lead
us
continu
promot
vaccin
exist
vaccin
even
improv
still
made
vaccin
mustelid
wide
success
use
coloni
mlv
ferret
avirul
strain
strain
onderstepoort
instanc
fulli
effect
dose
use
repres
one
tenth
dose
dog
rout
administr
subcutan
intramuscular
aerosolspray
rout
concern
latter
rout
adjust
dose
volum
difficult
gener
induc
lesser
degre
immun
recommend
take
great
care
vaccin
captiv
wild
carnivor
montali
et
al
principl
modifi
live
vaccin
avoid
unless
shown
total
safe
speci
involv
prepar
inactiv
vaccin
consid
carri
appel
colleagu
save
mustela
nigrip
black
foot
ferret
complet
disappear
carpent
et
al
adjuv
inactiv
iscom
vaccin
success
use
seal
immunogen
demonstr
pdvr
pdv
viral
strain
osterhau
et
al
visser
et
al
vaccin
use
present
provid
adequ
solut
immun
dog
cdv
thirti
year
still
scope
improv
total
protect
sign
f
cdv
diseas
die
epidemiolog
situat
canin
speci
enhanc
prevent
medicin
princip
tool
use
vaccin
could
also
improv
indic
attenu
vaccin
strain
certain
defici
regard
heat
stabil
specif
safeti
immunodefici
puppi
wild
carnivor
furthermor
safer
rout
administr
inject
could
use
oral
rout
instanc
practic
effect
vaccin
schedul
could
develop
combin
vaccin
one
promis
approach
offer
new
technolog
use
recombin
vaccin
varieti
virus
use
carrier
heterolog
gene
insert
recombin
dna
technolog
vaccinia
viru
commonli
use
vector
foreign
gene
panicali
paoletti
studi
undertaken
recent
year
evalu
safeti
suitabl
vaccinia
viru
eukaryot
express
vector
differ
mammalian
speci
includ
dog
appel
pastoret
et
al
safeti
efficaci
heatstabl
vacciniarabi
recombin
offer
excel
altern
attenu
strain
rabi
viru
current
use
field
achiev
immun
fox
kieni
et
al
potenc
recombin
vvrg
demonstr
canin
speci
chappui
et
al
experiment
vaccin
prepar
poxvitu
recombin
vaccinia
fowl
pox
canari
pox
includ
gene
f
h
measl
viru
canin
distemp
viru
test
mice
wild
et
al
mainli
dog
total
safeti
excel
immunogen
demonstr
vaccinationchalleng
trial
tartaglia
et
al
exampl
tabl
show
recent
result
obtain
laboratori
use
cdvcanari
pox
recombin
four
vaccin
puppi
receiv
inject
recombin
interv
pfudos
challeng
six
week
first
inject
total
protect
develop
antibodi
respons
seven
challeng
control
puppi
five
develop
distemp
three
die
result
therefor
highli
encourag
support
result
obtain
similar
recombin
new
approach
offer
prospect
posit
develop
improv
control
canin
distemp
would
like
conclus
quot
max
appel
erad
cdv
suggest
relat
measl
viru
man
may
desir
possibl
mani
speci
wild
carnivor
suscept
cdv
repres
constant
sourc
infect
togeth
diseas
dog
properli
vaccin
